Plexium Information

Plexium is the premier, next-generation targeted protein degradation (TPD) company. We lead the way in the rational design and discovery of Monovalent Direct Degraders and Molecular Glues. Our small molecule compounds are being developed as potential first-in-class and best-in-class treatments for high unmet medical needs. Our pipeline is powered by our DELTA Discovery™ platform, including a proprietary ultra-high throughput (uHTS) cell-based screening capability that has supported the advancement of multiple clinical-stage protein degraders. We leverage a suite of enabling technologies that expand the “druggable” target space for TPD and beyond.